ASSESSING MUCOSAL SURFACE AREA IN CELIAC DISEASE

这项拟议项目的长期目标是开发一种非侵入性的方法来定量评估与乳糜泻有关的肠粘膜表面积的范围。所提出的方法是基于这样的假设，即在某些实验条件下，粘膜表面积的变化可以定量地反映在13C标记的饱和长链脂肪酸的吸收中。因此，我们建议开发一种准确和非侵入性测量13C-棕榈酸吸收的方法，该剂量的13C-棕榈酸在标准的测试条件下被腹腔患者摄取。该方法是基于对患者摄入标准剂量的13C-棕榈酸和DyCl3后粪便样本中13C-过量/Dy的比率的测量。在这个项目的第一阶段，我们将通过对10名确诊为乳糜泻的儿童在实施无麸质饮食(GFD)前后进行适当的测量，证明我们方法的有效性。在项目的第二阶段，我们将展示肠黏膜受累程度与标记脂肪酸吸收之间的预期线性相关性。这项研究的结果将是提供一种用于这一目的的“检测试剂盒”，该试剂盒将用于常规临床应用和研究目的。拟议的商业应用：该项目将导致一种新的非侵入性工具的可用性，以评估黏膜表面积，以管理腹部患者。

The long-term objectives of this proposed project are to develop a noninvasive method for quantitative assessment of the extent of intestinal mucosal surface area involved in celiac disease. The proposed approach is based on the hypothesis that under certain experimental conditions changes in mucosal surface area are quantitatively reflected in the absorption of a dose of 13C-labeled saturated long-chain fatty acid. Thus, we propose to develop a method for accurate and noninvasive measurement of absorption of a dose of 13C-palmitic acid ingested under standard test conditions by the celiac patients. The method is based on measurement of the ratio of 13C-Excess/Dy in a sample of feces from the patient after ingestion of a standard dose of 13C-palmitic acid and DyCl3. During Phase-I of this project, we will show the validity of our approach by making appropriate measurements in ten children with firm celiac diagnosis before and after institution of a gluten free diet (GFD) which is the standard therapy for this disease. During Phase-II of the project, we will show the expected linear correlation between the extent of intestinal mucosal involvement and absorption of the labeled-fatty acid. The outcome of this research will be availability of a "Test Kit" for this purpose, which will be marketed both for routine clinical applications and for research purposes. PROPOSED COMMERCIAL APPLICATIONS: This project will lead to availability of a new noninvasive tool to evaluate mucosal surface area for management of celiac patients.